Frovatriptan: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) m (→Category) |
||
| Line 12: | Line 12: | ||
'''Frovatriptan''' (trade name '''Frova''') is a [[triptan]] [[medication|drug]] developed by [[Vernalis]] for the treatment of [[migraine]][[headache]]s, in particular those associated with [[menstruation]]. The product is licensed to [[Endo Pharmaceuticals]] in North America and[[Menarini]] in Europe.<ref>{{cite web |title=Frova |url=http://www.vernalis.com/ver/rdc2/pain/frovatriptan/ |publisher=Vernalis |accessdate=2007-11-28}}</ref> | '''Frovatriptan''' (trade name '''Frova''') is a [[triptan]] [[medication|drug]] developed by [[Vernalis]] for the treatment of [[migraine]][[headache]]s, in particular those associated with [[menstruation]]. The product is licensed to [[Endo Pharmaceuticals]] in North America and[[Menarini]] in Europe.<ref>{{cite web |title=Frova |url=http://www.vernalis.com/ver/rdc2/pain/frovatriptan/ |publisher=Vernalis |accessdate=2007-11-28}}</ref> | ||
==Category== | ==Category== | ||
Antimigraine Drugs, Triptans | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 22:25, 9 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Frovatriptan, click here
Synonyms / Brand Names: FROVA®
Overview
Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraineheadaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America andMenarini in Europe.[1]
Category
Antimigraine Drugs, Triptans
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Frovatriptan binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of FROVA is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
References